[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-diseases-metabolic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-diseases-metabolic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,80,127,154,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100268136","evaluation-of-children-with-endocrine-and-metabolic-related-conditions-100268136",false,"NCT02769975","Evaluation of Children With Endocrine and Metabolic-Related Conditions","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Participants with known or suspected endocrine disorder age 3 months-18 years are eligible for this protocol.\n* Relatives ages 3 months-100 years may be enrolled if clinically indicated for the diagnosis of a proband.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Lack of suspected endocrine disorders.\n* Any medical, physical, psychiatric, or social conditions, which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the patient, will exclude participation. Patients who are critically ill, unstable, or with severe organ failure that may affect\u002Flimit the endocrine evaluation and place unsustainable demands on Clinical Center or NICHD resources will be excluded.","ALL","3 Months","100 Years",{"count":19,"type":20},15000,"ESTIMATED","OBSERVATIONAL","Background:\n\nEndocrine glands give off hormones. Researchers want to learn more about the disorders that affect these glands in children. These disorders might be caused by changes in genes. Genes contain DNA, which is the blueprint of how a cell works. Researchers want to identify the genes involved in endocrine and metabolic disorders. This might help develop new ways to diagnose and treat the disorders.\n\nObjective:\n\nTo study the inheritance of endocrine or metabolism disorders.\n\nEligibility:\n\nChildren ages 3month-18 with known or suspected endocrine or metabolism disorders.\n\nFamily members ages 3months-100. They may participate in the DNA part of the study.\n\nDesign:\n\nParticipants will be screened with a review of their medical records. Their parents or guardians will allow the records to be released.\n\nParticipants will have a clinic visit. This may include a physical exam and medical history.\n\nParents or guardians will give their consent for the study. Participants may have tests, surgery, or other procedures to help diagnose or treat their condition. These could include:\n\nBlood, urine, and saliva tests\n\nGrowth hormone test\n\nPituitary and adrenal function tests\n\nPicture of chromosomes\n\nImaging tests. These may include X-ray, ultrasound, scans, or a skeletal survey.\n\nGenetic tests\n\nSleep study\n\nMedical photographs\n\nIf surgery is done, a tissue sample will be taken.\n\nParticipants may have follow-up visits for diagnosis and treatment.\n\nParticipating relatives will have one visit. This will include medical history and blood and saliva tests. The blood and saliva will be used for DNA testing.",[24,25,26,27,28],"Adrenal Insufficiency","Growth Disorder","Endocrine Diseases","Metabolic Disease","Bone Diseases, Metabolic",[30,31,32,25,33],"Endocrinology","Obesity","Pediatric","Pubertal Development","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2016-07-12",{"date":42,"type":20},"2030-12-31",{"name":44,"class":45},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":15,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100314492","clinical-and-molecular-characteristics-of-primary-aldosteronism-in-blacks-100314492","NCT03374215","Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks","* INCLUSION CRITERIA:\n\nInclusion criteria for main study:\n\n* Age greater than or equal to 18y.\n* Self-described Black race. Those with reported other racial backgrounds may enroll in protocol 00-CH-0160 instead.\n* Evidence supportive of the diagnosis of PA (e.g. HTN, hypokalemia, known adrenal nodule, elevated ARR, etc).\n* Willing and able to return to the NIH for follow-up evaluation.\n\nInclusion criteria for blood (peripheral) DNA only study:\n\n* Age greater than or equal to 7y.\n* Relative of a patient that participates in the main study (above) (i) with family history of hypertension, ACTs, or both, or (ii) with a genetic mutation identified in the course of the genetic investigations described in the main study.\n\nEXCLUSION CRITERIA:\n\nExclusion criteria for main study:\n\n* Individuals over the age of 70 years will be excluded because of the possibility of comorbidities that may significantly affect appropriate initial work-up and post-operative management. In addition, research data may be compromised by the inability to interpret data collected from patients over the age of 70 years that may be on multiple medications for a variety for reasons.\n* Women who are pregnant or nursing will be excluded for safety concerns with hyperaldosteronism workup.\n* Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing (e.g. NYHA Class III or IV heart failure, or CKD Stage 3b or worse), or who in the opinion of the investigators have unacceptably high risk for surgical morbidity and mortality (e.g. Revised Cardiac Risk Index Class IV or above, or American Society of Anesthesiologists Physical Status Class 3 or above) will be excluded from the protocol, as they will not be able to participate profitably in the research aspects of this protocol.\n* Individuals who have current substance abuse or a psychiatric disorder or any other condition that in the opinion of the investigators would impede competence, compliance, or participation in the study.\n* Individuals found to have a known inherited syndrome as the cause for hormone over-secretion will be excluded from participation in this protocol, as the mechanisms of hormone over-secretion and tumorigenesis is likely to be distinct in these individuals. Specific examples of syndromes that may be excluded from this protocol include individuals with Carney complex, McCune-Albright syndrome, and MEN-1. If inquiries are received from such patients, they will be referred to the appropriate ongoing protocols, if possible.\n* Family members who end up being diagnosed with PA will be referred to the 00-CH-0160 protocol, to avoid selection bias in genetic mutation analyses for PA.\n* Patients unwilling or unable to abide by procedures of the protocol.\n\n\\\u003CTAB\\>\n\nExclusion criteria for the DNA only study:\n\n-Patients unwilling or unable to provide peripheral blood for DNA studies.",true,"7 Years","70 Years",{"count":57,"type":20},1150,"Background:\n\nThe adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium. The cause of these tumors is unknown, but sometimes they are inherited.\n\nObjective:\n\nTo study the genes that may cause primary aldosteronism in Black individuals.\n\nEligibility:\n\nPeople ages 18-70 who:\n\nAre Black, African American, or of Caribbean descent\n\nAnd have difficult to control blood pressure or primary aldosteronism\n\nRelatives of people with primary aldosteronism\n\nDesign:\n\nParticipants who are relatives of people with primary aldosteronism will have only 1 visit, with medical history and blood tests.\n\nParticipants with primary aldosteronism or difficult to control blood pressure (suspected to possibly have primary aldosteronism) will be screened with a 1-2 hour visit. If they qualify, they will return for a hospital stay for 7-10 days. Tests may include:\n\nMedical history\n\nPhysical exam\n\nBlood tests: Participants will have a small tube (IV catheter) inserted in a vein in the arm. They may drink a glucose-containing liquid or get a salt solution. If medically indicated, they may have invasive blood tests with a separate consent.\n\nUrine tests: Some require a high-salt diet for 3 days.\n\nHeart tests\n\nScans: Participants lie in a machine that takes pictures of the body. A dye may be injected through a vein.\n\nSmall hair sample taken from near the scalp.\n\nKidney ultrasound\n\nBone density scan: Participants lie on a table while a camera passes over the body.\n\nIf the doctors feel it is medically necessary, they will offer participants treatment depending on their results. These treatments may cure the patient of their disease and may include:\n\n1. Having one adrenal gland removed by the Endocrine surgeon under anesthesia. Patients will have follow-up visits 2-4 weeks after surgery.\n2. Taking drugs to block the effects of aldosterone\n\nParticipants may return about 1 year later to repeat testing.",[60,61,28,62,63],"Adrenal Gland Neoplasm","Hypertension","Cardiovascular Disease","Hyperinsulinemia",[65,66,67,68,69,70],"Adrenal Adenoma","Molecular Genetics","African-American","Biomarkers","Primary Aldosteronism","Natural History","2026-06-10",{"date":73,"type":38},"2026-06-11",{"date":75,"type":38},"2017-12-14",{"date":77,"type":20},"2026-12-31",{"name":79,"class":45},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":53,"sex":15,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":110,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100557135","digital-diagnostics-and-intervention-services-for-parkinsons-disease-100557135","NCT06534177","Digital Diagnostics and Intervention Services for Parkinson's Disease","Development of Digital Diagnostics and Intervention Services for Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \\[stroke, multiple sclerosis, arthritis or osteoporosis\\]\n* Able to self-report history of daily gait freezing and\u002For festination for people with PD or gait and\u002For transfers affected by condition\n* Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands Healthy participants \\[Phase 1,2,3\\]\n* With no long-term conditions affecting movement\n* Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and\n* if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands\n\nExclusion Criteria:\n\n* Participants with long-term conditions affecting movement\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system Healthy participants\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system","18 Years",{"count":89,"type":20},80,"People with Parkinson's have infrequent clinical consultation (once every 12-18 months) and limited rehabilitation.\n\nAssessment play an important role in these consultations to help clinicians understand patients' health status and disease progression necessary to adjust treatment plans. The current way of measuring is the UPDRS which needs a clinician to do this and takes 30 minutes. There is a strong need for more frequent and accurate Parkinson's assessments in the clinic and at home to detect changes early and then give appropriate support and drug and physiotherapy quickly. There is a need to develop good home digital physiotherapy tools to increase the amount of therapy. Here the investigators are testing new digital technologies to do these assessments in the home and clinic and a new digital physiotherapy device in the home. The investigators aim to conduct a clinical study with 50 people with Parkinson's (50 from UK) with the UPDRS, (a rating scale that is commonly used in clinical settings to evaluate the progression of Parkinson's disease) and 30 healthy adults. The investigators will develop and investigate if two new digital devices, one the MachineMD that measures eye movement and one the gaitQ that measures gait can be used instead of the MDS-UPDRS (motor) using digital gait and ophthalmic features in the clinic setting. The investigators will investigate the effect of a physiotherapy gait intervention gaitQ Tempo in the home context for two weeks and of doing the gait measure at home. The investigators will determine the potential of the gaitQ intervention to improve key gait metrics in order to collect clinical evidence and of using the gaitQ as a cuing system over a 2-week period on gait and other movement measures in the home and community",[92,93,94,95,96,97,98,99,100,101,102,103,104,105,28,106,107,108,109],"Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Joint Diseases","Musculoskeletal Diseases","Parkinson Disease","Basal Ganglia Diseases","Movement Disorders","Synucleinopathies","Neuro-Degenerative Disease","Demyelinating Disease, Autoimmune, CNS","Demyelinating Disease","Autoimmune Diseases","Immune System Diseases","Bone Diseases","Arthritis","Osteoporosis","Multiple Sclerosis",[111,112,113,114,115],"parkinson's disease","osteoarthritis","stroke","MS","osteoporosis","NOT_YET_RECRUITING","2024-08-06",{"date":119,"type":38},"2024-08-09",{"date":121,"type":20},"2024-10-15",{"date":123,"type":20},"2026-03-01",{"name":125,"class":126},"University of Exeter","OTHER",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":53,"sex":15,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100403065","the-impact-of-glomerular-disorders-on-bone-quality-and-strength-100403065","NCT04528446","The Impact of Glomerular Disorders on Bone Quality and Strength","BoneGN","Inclusion Criteria for participants with glomerular disease:\n\n1. CureGN participant or CureGN Eligible\n\n   CureGN eligible is defined as having a diagnosis of Glomerulonephropathy (GN). Patients would otherwise be enrolled in be in CureGN study, except for lacking a minor entry criteria, such as:\n   1. First diagnostic kidney biopsy within 5 years of CureGN study enrollment\n   2. Access to first kidney biopsy report and\u002For slides or not being interested in study participation.\n2. Males or females 5 to 55 years (premenopausal for women)\n3. Females must have a negative urine\u002Fserum pregnancy test\n4. Stable doses of nutritional vitamin D or active vitamin D therapy for at least 3 months before enrollment ((if on either form of Vitamin D)\n5. Consent\u002FParental\u002Fguardian permission (informed consent) and if appropriate, child assent\n\nExclusion Criteria for all participants\n\n1. Chronic Dialysis\n2. Solid organ transplantation\n3. Lower extremity amputations or non-ambulatory\n4. Malignancy requiring chemotherapy or metastatic to bone\n5. Metabolic bone disease (e.g., Paget's disease, primary hyperparathyroidism)\n6. Endocrinopathy (current hyperthyroidism or untreated hypothyroidism, Cushing's syndrome)\n7. Medical diseases (end stage liver disease, heart or lung disease, intestinal malabsorption)\n8. Those treated with bisphosphonates, teriparatide, calcitonin, selective estrogen receptor modulators, estrogen, or phenytoin in the past 12 months\n9. Previous bilateral wrist and tibia fractures\n10. Pregnant or lactating females\n11. Parents\u002Fguardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.","5 Years","55 Years",{"count":137,"type":20},270,"The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.",[140,28,141],"Glomerular Disease","Bone Fracture",[143,141],"Kidney Disease","2024-06-28",{"date":146,"type":38},"2024-07-01",{"date":148,"type":38},"2019-06-14",{"date":150,"type":20},"2024-12",{"name":152,"class":126},"Columbia University",2,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":162,"minAge":87,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100542178","the-bone-metabolism-characteristics-of-premature-ovarian-insufficiency-100542178","NCT06339489","The Bone Metabolism Characteristics of Premature Ovarian Insufficiency","Explore the Bone Metabolism Characteristics of Premature Ovarian Insufficiency","POI","Inclusion Criteria:\n\nPatients diagnosed by Western medicine with premature ovarian insufficiency. 18 ≤ patients' age ≤ 39 years;. Patients who voluntarily participate in this study, sign an informed consent form.\n\nExclusion Criteria:\n\nPatients with congenital gonadal dysplasia or a family history similar to \"early menopause\".\n\nPOI patients with acquired organic lesions or ovarian surgery. Patients who have taken Western or herbal medicine artificial cycle therapy or other endocrine therapy in the past three months.\n\nPatients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system.\n\nPatients who are breastfeeding or pregnant.","FEMALE","39 Years",{"count":165,"type":20},60,"Explore the bone metabolism characteristics of premature ovarian insufficiency.",[168,28,169],"Premature Ovarian Insufficiency","Bone Mineral Density","2024-06-21",{"date":172,"type":38},"2024-06-25",{"date":174,"type":38},"2024-04-01",{"date":176,"type":20},"2025-02-01",{"name":178,"class":126},"Shi Yun",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":53,"sex":15,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":46},"100544382","exosome-micrornas-as-potential-biomarkers-of-metabolic-bone-disease-of-prematurity-100544382","NCT06368154","Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity","Prospective Cohort Study of Exosomal microRNAs as Biomarkers for Diagnosis and Therapeutic Efficacy Evaluation of Metabolic Bone Diseases in Premature Infants","Inclusion Criteria:\n\n* The gestational age was 37+0-41+6 weeks and the age was less than 28 days\n\nExclusion Criteria:\n\n* There was no blood transfusion, no operation, no congenital malformation, no inherited metabolic diseases, no history of intravenous nutrition, and no intestinal diseases","0 Hours","72 Hours",{"count":189,"type":20},200,"Metabolic bone disease of prematurity (MBDP) is caused by insufficient content of calcium, phosphorus, and organic protein matrix in preterm infants or bone metabolism disorder, which is one of the complications affecting the quality of life of preterm infants. The early symptoms of MBDP are insidious, and there is no unified and clear diagnostic method. The diagnosis is mostly based on typical clinical manifestations and X-ray findings, but at this time, bone mineral density has decreased significantly, so early detection and diagnosis are difficult. Studies have shown that exosomal micrornas have biological characteristics and targeting specificity, and can be used as new molecular diagnostic markers for diseases. Several studies have reported the use of plasma or serum microRNAs as molecular markers for early prediction of bone diseases. In our previous study, we extracted plasma exosomes from preterm infants for high-throughput sequencing of microRNAs, and identified differentially expressed micrornas related to bone metabolism. In this study, exosomes were used as carriers, and digital PCR was used to verify the specificity and sensitivity of plasma exosomal microRNA as biomarkers of MBDP in a large sample size. The above biomarkers were compared and verified before and after treatment in children with MBDP. Further revealing plasma exosomal microRNA as a biological indicator for evaluating the efficacy of MBDP may improve the diagnostic level of MBDP, improve the outcome and prognosis of very low birth weight preterm infants, thereby improving global health and reducing socioeconomic costs.",[192,193,28],"Exosomes","Newborn","2024-04-15",{"date":196,"type":38},"2024-04-16",{"date":198,"type":38},"2024-01-01",{"date":77,"type":20},{"name":201,"class":202},"Hunan Children's Hospital","OTHER_GOV"]